![Prevalence of side-effects associated with the booster dose of Pfizer- BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia - ScienceDirect Prevalence of side-effects associated with the booster dose of Pfizer- BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S259008892200052X-gr1.jpg)
Prevalence of side-effects associated with the booster dose of Pfizer- BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia - ScienceDirect
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://www.thelancet.com/cms/attachment/97d1c5ff-af79-4d10-b5b8-3026a35a572d/gr1_lrg.jpg)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
![Vaccines | Free Full-Text | Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects Vaccines | Free Full-Text | Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects](https://www.mdpi.com/vaccines/vaccines-09-00556/article_deploy/html/images/vaccines-09-00556-g001.png)
Vaccines | Free Full-Text | Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects
![Vaccines | Free Full-Text | Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia Vaccines | Free Full-Text | Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia](https://www.mdpi.com/vaccines/vaccines-10-00223/article_deploy/html/images/vaccines-10-00223-g001.png)
Vaccines | Free Full-Text | Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia
![Study: the third dose of Comirnaty prevents death, severe disease and hospitalization – vaktsineeri.ee Study: the third dose of Comirnaty prevents death, severe disease and hospitalization – vaktsineeri.ee](https://vaktsineeri.ee/wp-content/uploads/2021/03/210128-pfizer-editorial.jpeg)
Study: the third dose of Comirnaty prevents death, severe disease and hospitalization – vaktsineeri.ee
![COVID-19 Vaccine Boosters vs. Third Doses: Frequently Asked Questions - Anne Arundel County Department of Health COVID-19 Vaccine Boosters vs. Third Doses: Frequently Asked Questions - Anne Arundel County Department of Health](https://www.aahealth.org/wp-content/uploads/2022/04/Booster-Infographic_tw_05_18_22.png)
COVID-19 Vaccine Boosters vs. Third Doses: Frequently Asked Questions - Anne Arundel County Department of Health
![Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7013e3_COVIDVaccineFieldEffectiveness_IMAGE_29Mar21_v2_1200x627.jpg?_=23735)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December
![Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study - The Lancet Infectious Diseases Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/7936827d-8890-464f-9165-30c98891fdfa/gr1.jpg)
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study - The Lancet Infectious Diseases
![Frontiers | Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population Frontiers | Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population](https://www.frontiersin.org/files/Articles/834744/fpubh-10-834744-HTML-r1/image_m/fpubh-10-834744-g001.jpg)
Frontiers | Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population
![Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 | European Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 | European](https://ejhp.bmj.com/content/ejhpharm/early/2021/07/27/ejhpharm-2021-002933/F2.large.jpg)
Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 | European
![COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 | MMWR COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm705152a1_VaccineSafetyChildren_Image_31Dec21_1200x675.jpg)